Lars Fugger

Lars Fugger

Auto-generated profile, based on publicly available information

Lars Fugger

Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Cell
Verified
Journal Article
Closed access
LFLars Fugger
Lars Fugger
LJLise Torp Jensen
Lise Torp Jensen
JRJamie Rossjohn
Jamie Rossjohn

4 May 2022 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
KAKathrine E. Attfield
Kathrine E. Attfield
LJLise Torp Jensen
Lise Torp Jensen
MKMax Kaufmann
Max Kaufmann
MFManuel A. Friese
Manuel A. Friese
LFLars Fugger
Lars Fugger

8 July 2012 in Nature
Verified
Journal Article
Open access
PDF file
AGAdam P. Gregory
Adam P. Gregory
Calliope DendrouCalliope Dendrou
Calliope Dendrou
KAKathrine E. Attfield
Kathrine E. Attfield
AHAiden Haghikia
Aiden Haghikia
DXDionysia K. Xifara
Dionysia K. Xifara
LFLars Fugger
Lars Fugger
Genome-wide association studies in combination with functional analyses identify a genetic variant that explains why anti-tumour necrosis factor therapy, used in several autoimmune diseases, exacerbates multiple sclerosis. Recent genome-wide association studies (GWAS) have indicated an association between multiple sclerosis and a single-nucleotide polymorphism in the TNFRSF1A gene that encodes tumour necrosis factor (TNF) receptor 1 (TNFR1). TNF has previously been implicated in autoimmunity and TNF antagonists are effective treatments in several autoimmune diseases, but not in multiple sclerosis. Interestingly, GWAS evidence shows no link between TNFRSF1A and multiple sclerosis. This study compares GWAS results across different autoimmune conditions, as well as findings from functional and biophysical investigations, to show that multiple sclerosis-associated genetic risk at the TNFR1 locus results in the generation of a novel, endogenous TNF antagonist. This genetic-risk effect parallels the effects of anti-TNF therapy, which has been reported — in rare cases — to induce clinical onset of multiple sclerosis. Although there has been much success in identifying genetic variants associated with common diseases using genome-wide association studies (GWAS)1, it has been difficult to demonstrate which variants are causal and what role they have in disease. Moreover, the modest contribution that these variants make to disease risk has raised questions regarding their medical relevance2. Here we have investigated a single nucleotide polymorphism (SNP) in the TNFRSF1A gene, that encodes tumour necrosis factor receptor 1 (TNFR1), which was discovered through GWAS to be associated with multiple sclerosis (MS)3,4, but not with other autoimmune conditions such as rheumatoid arthritis5, psoriasis6 and Crohn’s disease7. By analysing MS GWAS3,4 data in conjunction with the 1000 Genomes Project data8 we provide genetic evidence that strongly implicates this SNP, rs1800693, as the causal variant in the TNFRSF1A region. We further substantiate this through functional studies showing that the MS risk allele directs expression of a novel, soluble form of TNFR1 that can block TNF. Importantly, TNF-blocking drugs can promote onset or exacerbation of MS9,10,11, but they have proven highly efficacious in the treatment of autoimmune diseases for which there is no association with rs1800693. This indicates that the clinical experience with these drugs parallels the disease association of rs1800693, and that the MS-associated TNFR1 variant mimics the effect of TNF-blocking drugs. Hence, our study demonstrates that clinical practice can be informed by comparing GWAS across common autoimmune diseases and by investigating the functional consequences of the disease-associated genetic variation.

2 November 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Calliope DendrouCalliope Dendrou
Calliope Dendrou
ACAdrian Cortes
Adrian Cortes
LSLydia Shipman
Lydia Shipman
HEHayley G. Evans
Hayley G. Evans
KAKathrine E. Attfield
Kathrine E. Attfield
LFLars Fugger
Lars Fugger
Resolving TYK2 locus genotype-to-phenotype differences reveals an immune signaling optimum that may be exploited therapeutically for treating autoimmune diseases.

23 June 2005 in Brain
Verified
Journal Article
Open access
PDF file
MFManuel A. Friese
Manuel A. Friese
LFLars Fugger
Lars Fugger
Multiple sclerosis afflicts more than 1 million individuals worldwide and is widely considered to be an autoimmune disease. Traditionally, CD4+ T helper cells have almost exclusively been held responsible for its immunopathogenesis, partly because certain MHC class II alleles clearly predispose for developing multiple sclerosis and also, because of their importance in inducing experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis. However, several strategies that target CD4+ T cells beneficially in EAE have failed to ameliorate disease activity in multiple sclerosis, and some have even triggered exacerbations. Recently, the potential importance of CD8+ T cells has begun to emerge. Physiologically, CD8+ T cells are essential for detecting and eliminating abnormal cells, whether infected or neoplastic. In multiple sclerosis, genetic associations with MHC class I alleles have now been established, and CD8+ as well as CD4+ T cells have been found to invade and clonally expand in inflammatory central nervous system plaques. Recent animal models induced by CD8+ T cells show interesting similarities to multiple sclerosis, in particular, in lesion distribution (more inflammation in the brain relative to the spinal cord), although not all of the features of the human disease are recapitulated. Here we outline the arguments for a possible role for CD8+ T cells, a lymphocyte subset that has long been underrated in multiple sclerosis and should now be considered in new therapeutic approaches.

26 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JHJesse Huang
Jesse Huang
MKMohsen Khademi
Mohsen Khademi
LFLars Fugger
Lars Fugger
ÖLÖrjan Lindhe
Örjan Lindhe
LNLenka Novakova
Lenka Novakova
IKIngrid Kockum
Ingrid Kockum
Effective biomarkers for multiple sclerosis diagnosis, assessment of prognosis, and treatment responses, in particular those measurable in blood, are largely lacking. We have investigated a broad set of protein biomarkers in cerebrospinal fluid (CSF) and plasma using a highly sensitive proteomic immunoassay. Cases from two independent cohorts were compared with healthy controls and patients with other neurological diseases. We identified and replicated 10 cerebrospinal fluid proteins including IL-12B, CD5, MIP-1a, and CXCL9 which had a combined diagnostic efficacy similar to immunoglobulin G (IgG) index and neurofilament light chain (area under the curve [AUC] = 0.95). Two plasma proteins, OSM and HGF, were also associated with multiple sclerosis in comparison to healthy controls. Sensitivity and specificity of combined CSF and plasma markers for multiple sclerosis were 85.7% and 73.5%, respectively. In the discovery cohort, eotaxin-1 (CCL11) was associated with disease duration particularly in patients who had secondary progressive disease ( P CSF < 4 × 10 −5 , P plasma < 4 × 10 −5 ), and plasma CCL20 was associated with disease severity ( P = 4 × 10 −5 ), although both require further validation. Treatment with natalizumab and fingolimod showed different compartmental changes in protein levels of CSF and peripheral blood, respectively, including many disease-associated markers (e.g., IL12B, CD5) showing potential application for both diagnosing disease and monitoring treatment efficacy. We report a number of multiple sclerosis biomarkers in CSF and plasma for early disease detection and potential indicators for disease activity. Of particular importance is the set of markers discovered in blood, where validated biomarkers are lacking.